bill hunter cardiome

September 21, 2012 By Leave a Comment

In early July, after a disastrous few months that saw the company's stock fall from nearly three dollars to less than $.40 cents, Cardiome announced that CEO Doug Janzen had left the company and was to be replaced by board member and former Angiotech Pharmaceuticals CEO Bill Hunter.

In early July, after a disastrous few months that saw the company’s stock fall from nearly three dollars to less than $.40 cents, Cardiome announced that CEO Doug Janzen had left the company and was to be replaced by board member and former Angiotech Pharmaceuticals CEO Bill Hunter.

Filed Under:
About Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.